CBPO [China Biologic Products] 8-K: REGISTRATION RIGHTS AGREEMENT Agreement Company Purchaser This Registration

[REGISTRATION RIGHTS AGREEMENT Agreement Company Purchaser This Registration Rights Agreement (this “ RECITALS Selling Stockholder Purchase Agreement Shares Common Stock The Company and the Purchaser hereby agree as follows: Definitions 1. 2009 Holders “ 2010 Holders “ Advice “ Affiliate “ Agreement “ Business Day “ Company “ Commission “ Common Stock “ Effectiveness Date “ Effectiveness Period “ Exchange] []

CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[JOINT FILING AGREEMENT Dated: May 15, 2013 WP X Biologics LLC Scott A. Arenare Attorney-in-Fact* WARBURG PINCUS PRIVATE EQUITY X, L.P.] [REGISTRATION RIGHTS AGREEMENT Agreement Company Purchaser This Registration Rights Agreement (this “ RECITALS Selling Stockholder Purchase Agreement Shares Common Stock The Company and the Purchaser hereby agree as follows: Definitions 1. 2009 Holders “ 2010 Holders “ Advice “ Affiliate “ Agreement “ Business Day “ Company “ Commission “ Common Stock “ Effectiveness Date “ Effectiveness Period “ Exchange] [ESCROW AGREEMENT WP X Biologics LLC Ms. Lin Ling Li WHEREAS, NOW THEREFORE 1. Appointment The Parties hereby appoint the Escrow Agent as their escrow agent for the purposes set forth herein, and the Escrow Agent hereby accepts such appointment under the terms and conditions set forth herein. 2. Escrow Document 2.1 Party B agrees to deposit with the Escrow] [AGREEMENT Agreement WP X Ms. Li Mr. Lin Parties Party This AGREEMENT (this “ WHEREAS Share Purchase Agreement WHEREAS Escrow Agreement Escrow Agent WHEREAS NOW, THEREFORE 1. Definitions 2. Delivery of Release Notice (a) HK Lawsuit Resolution Plaintiffs (b) Within ten (10) Business Days of the HK Lawsuit Resolution, the Parties shall deliver the Release Notice to the Escrow Agent] [CUSIP No. 16938C106 2 1. Names of reporting persons.]

CBPO [China Biologic Products] SC 13D/A: JOINT FILING AGREEMENT Dated: May 15, 2013 WP

[JOINT FILING AGREEMENT Dated: May 15, 2013 WP X Biologics LLC Scott A. Arenare Attorney-in-Fact* WARBURG PINCUS PRIVATE EQUITY X, L.P.] [REGISTRATION RIGHTS AGREEMENT Agreement Company Purchaser This Registration Rights Agreement (this “ RECITALS Selling Stockholder Purchase Agreement Shares Common Stock The Company and the Purchaser hereby agree as follows: Definitions 1. 2009 Holders “ 2010 Holders “ Advice “ Affiliate “ Agreement “ Business Day “ Company “ Commission “ Common Stock “ Effectiveness Date “ Effectiveness Period “ Exchange] [ESCROW AGREEMENT WP X Biologics LLC Ms. Lin Ling Li WHEREAS, NOW THEREFORE 1. Appointment The Parties hereby appoint the Escrow Agent as their escrow agent for the purposes set forth herein, and the Escrow Agent hereby accepts such appointment under the terms and conditions set forth herein. 2. Escrow Document 2.1 Party B agrees to deposit with the Escrow] [AGREEMENT Agreement WP X Ms. Li Mr. Lin Parties Party This AGREEMENT (this “ WHEREAS Share Purchase Agreement WHEREAS Escrow Agreement Escrow Agent WHEREAS NOW, THEREFORE 1. Definitions 2. Delivery of Release Notice (a) HK Lawsuit Resolution Plaintiffs (b) Within ten (10) Business Days of the HK Lawsuit Resolution, the Parties shall deliver the Release Notice to the Escrow Agent] [CUSIP No. 16938C106 2 1. Names of reporting persons.]

CBPO [China Biologic Products] 8-K: (Original Filing)

[FOR RELEASE May 8, 2013 China Biologic Reports Financial Results for the First Quarter of 2013 1Q13 Total Sales Increases 14.4% to $54.0 Million 1Q13 Operating Margin Increases to 48.1% from 1Q13 Non-GAAP Net Income 29.0% to $16.4 Million Increases BEIJING, China – May 8, 2013 – First Quarter 2013 Financial Highlights · Total sales · Gross profit · Income] []

CBPO [China Biologic Products] 8-K: FOR RELEASE May 8, 2013 China Biologic Reports

[FOR RELEASE May 8, 2013 China Biologic Reports Financial Results for the First Quarter of 2013 1Q13 Total Sales Increases 14.4% to $54.0 Million 1Q13 Operating Margin Increases to 48.1% from 1Q13 Non-GAAP Net Income 29.0% to $16.4 Million Increases BEIJING, China – May 8, 2013 – First Quarter 2013 Financial Highlights · Total sales · Gross profit · Income] []

CBPO [China Biologic Products] 10-Q: (Original Filing)

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. IN th David (Xiaoying) Gao Chief Executive Officer] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. IN th Ming Yang Chief Financial Officer (Principal Financial Officer)]

CBPO [China Biologic Products] 10-Q:

[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. IN th David (Xiaoying) Gao Chief Executive Officer] [1. 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. IN th Ming Yang Chief Financial Officer (Principal Financial Officer)]

CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT Agreement Purchaser Seller Seller Affiliate Parties Party This SHARE PURCHASE AGREEMENT (this “ Common Stock Company WHEREAS, Seller desires to sell to Purchaser, and Purchaser desires to purchase from Seller, an aggregate of 3,112,920 shares of common stock (“ NOW THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 5)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) 18th Floor, Jialong International Building, 19 People's Republic of China (+86) 10-6598-3111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 29, 2013 (Date of Event]

CBPO [China Biologic Products] SC 13D/A: STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT Agreement

[STRICTLY CONFIDENTIAL Execution Version SHARE PURCHASE AGREEMENT Agreement Purchaser Seller Seller Affiliate Parties Party This SHARE PURCHASE AGREEMENT (this “ Common Stock Company WHEREAS, Seller desires to sell to Purchaser, and Purchaser desires to purchase from Seller, an aggregate of 3,112,920 shares of common stock (“ NOW THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 5)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) 18th Floor, Jialong International Building, 19 People's Republic of China (+86) 10-6598-3111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 29, 2013 (Date of Event]

CBPO [China Biologic Products] SC 13D/A: (Original Filing)

[Execution Version STRICTLY CONFIDENTIAL SHARE PURCHASE AGREEMENT Agreement Purchaser Seller Seller Affiliate Parties Party This SHARE PURCHASE AGREEMENT (this “ Common Stock Company WHEREAS, Seller desires to sell to Purchaser, and Purchaser desires to purchase from Seller, an aggregate of 3,112,920 shares of common stock (“ NOW THEREFORE, in consideration of the foregoing and the mutual promises, covenants and agreements] [16938C106 CUSIP No. 1. Names of Reporting Persons.]

Skip to toolbar